Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF

Cancer Gene Therapy

Volumn 4, Issue 3, 1997, Pages 157-166

  Aruga, Etsuko ^a   Aruga, Atsushi ^a   Arca, Marjorie J ^a   Lee, William M F ^b   Yang, Ning Sun ^c   Smith II, John W ^d   Chang, Alfred E ^a,e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Auragen Inc   (United States)

^d PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adoptive immunotherapy; Breast neoplasm; Cytokine; Gene therapy; GM CSF; IL 12

Indexed keywords

B7 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12;

ADENOCARCINOMA; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CYTOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LUNG TUMOR; LYMPH NODE; LYMPHOCYTE DEPLETION; METASTASIS; MOUSE; SECRETION; T LYMPHOCYTE SUBPOPULATION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD80; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; LUNG NEOPLASMS; LYMPH NODES; LYMPHOCYTE DEPLETION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031137564     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Miller AR, McBride WH, Hunt K, Economou JS. Cytokine-mediated gene therapy for cancer. Ann Surg Oncol. 1994;1:436-450.
2. Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ. In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol. 1996;23:88-100.
3. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol. 1996;23:101-107.
4. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
5. Connor J, Bannerji R, Saito S, et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med. 1993;177:1127-1134.
6. Greenberg, PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281-355.
7. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol. 1991;147:729-737.
8. Yoshizawa H, Sakai K, Chang AE, Shu S. Activation of anti-CDS of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol. 1991;134:473-479.
9. Yoshizawa H, Chang AE, Shu S. Cellular interaction in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res. 1992;52:1129-1136.
10. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2. J Clin Oncol. In press.
11. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
12. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 1995;154:6466-6474.
13. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.
14. Arca MJ, Krauss JC, Aruga A, et al. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther. 1996;3:39-47.
15. Margaretten NC, Witschi H. Effects of hyperoxia on growth characteristics of metastatic murine tumors in the lung. Cancer Res. 1988;48:2779-2783.
16. Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gunmediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA. 1996;93:6291-6296.
17. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA. 1987;84: 1374-1378.
18. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst. 1966;36:641-645.
19. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol. 1996;156:3821-3827.
20. Coughlin CM, Wysocka M, Kurzawa HL, Lee WMF, Trinchieri G, Eck SL. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 1995;55:4980-4987.
21. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
22. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor to a murine melanoma IH vivo. Cancer Res. 1994;54:182-189.
23. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12. J Immunol. 1995;155:1393-1403.
24. Colombo MP, Vagliani M, Spreafico F, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 1996;56:2531-2534.